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Abstract
The Collapsin Response Mediator Proteins (CRMPs) are highly expressed in the developing brain, and in adult brain areas
that retain neurogenesis, ie: the olfactory bulb (OB) and the dentate gyrus (DG). During brain development, CRMPs are
essentially involved in signaling of axon guidance and neurite outgrowth, but their functions in the adult brain remain
largely unknown. CRMP5 has been initially identified as the target of auto-antibodies involved in paraneoplasic neurological
diseases and further implicated in a neurite outgrowth inhibition mediated by tubulin binding. Interestingly, CRMP5 is also
highly expressed in adult brain neurogenic areas where its functions have not yet been elucidated. Here we observed in
both neurogenic areas of the adult mouse brain that CRMP5 was present in proliferating and post-mitotic neuroblasts, while
they migrate and differentiate into mature neurons. In CRMP5
2/2 mice, the lack of CRMP5 resulted in a significant increase
of proliferation and neurogenesis, but also in an excess of apoptotic death of granule cells in the OB and DG. These findings
provide the first evidence that CRMP5 is involved in the generation and survival of newly generated neurons in areas of the
adult brain with a high level of activity-dependent neuronal plasticity.
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Introduction
Collapsin response mediator protein 5 (CRMP5) is a member of
the collapsing response mediator protein family which is composed
of five cytosolic proteins widely expressed in the brain during
development, but also in some restricted areas of the adult brain
[1]. These proteins have been implicated in developmental events
like neuritic extension and axonal pathfinding and in some aspects
of neurodegenerative processes or neuronal repair [2–6]. CRMP5
has been the last member of the family to be identified in the
mouse [7] and rat [8], but also in man where this protein is the
main target of auto-antibodies developed by patients with
paraneoplasic neurological diseases [9,10]. Like the other
members of the family, CRMP5 is present in the embryonic
brain [2] where its expression is consistent with a function in the
permissiveness of neurite outgrowth [11], and in the regulation of
filopodial dynamics and growth cone development [6,12]. In the
post-natal brain, CRMP5 is co-expressed with CRMP2 in adult
oligodendrocytes where both proteins are involved in the
semaphorin-3A signaling pathway [9]. CRMP5 is also present in
neurons of the brain areas that retain neurogenesis, ie: the
olfactory bulb (OB) [13] and the dentate gyrus (DG) of the
hippocampus [14]. The subventricular zone (SVZ) of the lateral
ventricles and the subgranular zone (SGZ) of the DG in the
hippocampus are the two brain areas where adult neurogenesis
has only been consistently found [15,16]. In the SVZ, a subset of
quiescent GFAP positive radial cells (type B cells) have the
potential to serve as adult neural stem cells (NSCs) and generate
transit amplifying cells (type C cells), which in turn give rise to
doublecortin (DCX)-positive neuroblasts (type A cells). The
neuroblasts migrate towards the OB through the rostral migratory
stream (RMS), and they differentiate into olfactory bulb granular
or periglomerular interneurons. In the SGZ of the DG, a
population of GFAP/Nestin positive radial cells (type 1 cells)
generates actively self-renewing non-radial progenitors cells (type 2
cells) which give rise to DCX-positive neuroblasts that differentiate
into local glutamatergic granule cells. Many cell-intrinsic programs
and extrinsic signals control neurogenesis by regulating the
proliferation, fate determination, migration of progenitor cells
and the long term survival and integration of mature newborn
neurons [15–17].
The aim of the present study was to gain a better understanding
of CRMP5 putative functions in neurogenic areas of the adult
mouse brain, using mutant mice with a knock-out (KO) of the
CRMP5 gene. We established that in both adult brain neurogenic
areas, CRMP5 expression is restricted to mitotic and post-mitotic
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CRMP5
2/2 mice, the number of proliferating cells and the rate of
newly generated neurons were notably increased in both
neurogenic areas, but this phenomenon was balanced by an
excess of apoptotic neuronal death. Our results suggest that
CRMP5 is most likely involved in intracellular pathways which
determine the rate of generation and survival of newly generated
neurons in the two adult brain neurogenic areas.
Results
CRMP5 is constitutively expressed by doublecortin-
positive neuroblasts in the adult brain neurogenic areas
In the adult mouse forebrain, cells of the neuronal lineage
proliferate in the SVZ, migrate along the RMS and reach the OB
where they differentiate into interneurons [15]. As shown by
CRMP5 immunolabeling (Fig. 1), numerous densely-packed
Figure 1. Immunofluorescence labeling of CRMP5 expression in neuroblasts of the mouse olfactory neurogenic area. (A–C) Confocal
microscopy of immuno-labelled sections showing numerous CRMP5-positive cells at three levels of the olfactory neurogenic area, ie: the
subependymal layer of the OB (SEL-OB), the rostral migratory stream (RMS) and the subventricular zone (SVZ) of the forebrain. (D–O) Characterization
of CRMP5-positive cells in the SVZ. Double immunolabeling of CRMP5 and the glial markers GFAP (D–F) or S100 (G–I, arrow) revealed the lack of
CRMP5 expression in glial cells. In contrast, all CRMP5-positive cells co-expressed doublecortin (DCX) a selective marker of immature neurons (or
neuroblasts) (J–L, arrow). Finally, double immunolabeling of CRMP5 and KI67, a marker of cycling cells, shows that some CRMP5-positive cells are still
mitotic (M–O, arrow), whereas the majority are no longer proliferative. Lateral ventricles (LV). Optical thickness of the confocal planes=1 mm. Scale
bars 50 mm (A–C); 15 mm (D–I); 10 mm (J–L); 20 mm (M–O).
doi:10.1371/journal.pone.0023721.g001
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neurogenic area, ie: the subependymal layer (SEL) of the OB
(Fig. 1A), the RMS (Fig. 1B), and the SVZ (Fig. 1C). In the SVZ,
double immunolabeling shows that CRMP5 was neither co-
expressed with the glial markers GFAP (Fig. 1 D–F) or S100 (Fig. 1
G–I), nor with Nestin, a marker of transit amplifying (type ‘‘C’’)
cells (data not shown). By contrast, CRMP5 in the SVZ was
systematically co-localized with the neuroblast markers double-
cortin (DCX) (Fig. 1 J–L), PSA-NCAM and TUC4/CRMP4 (data
not shown). Since the SVZ contains cell populations with different
rates of proliferation, we performed a double immunolabeling of
CRMP5 with the cycling-cell marker KI67. As shown in Figure 1
M–O, a sub-population (17.863.6%) of CRMP5-expressing cells
is still cycling (KI67-positive). These CRMP5-positive cycling cells
represented 48.369.6% of the entire population of KI67-positive
proliferating cells in the SVZ.
In the adult hippocampus, CRMP5 is highly expressed in the
SGZ of the DG (Fig. 2 A, B). As already observed in the SVZ,
double immunolabeling of CRMP5 with markers of glial cells
(GFAP/S100; Fig. 2 C–E and 2 F–H) or transit amplifying cells
(Nestin; data not shown) failed to reveal any co-expression. By
contrast, all CRMP5-positive cells systematically co-expressed the
neuroblast specific markers DCX (Fig. 2 I–K), PSA-NCAM and
TUC4/CRMP4 (data not shown). Furthermore, double labeling
of CRMP5 with KI67, a marker of cycling cells, (Fig. 2 L–N)
revealed that 30.365.4% of CRMP5-positive cells co-expressed
KI67 and were still proliferating in the DG, whereas 43.969.4%
of KI67-positive cells were CRMP5-positive.
Altogether, our findings indicate that in both adult forebrain
neurogenic areas, CRMP5 expression is restricted to mitotic and
post-mitotic neuroblasts, the most numerous CRMP5-positive
neuroblasts being post-mitotic cells probably engaged in the
migration and differentiation processes.
Suppression of CRMP5 expression increases cell
proliferation in the adult brain neurogenic areas
Since CRMP5 is highly expressed in neuroblasts of both
neurogenic areas, including a sub-population of proliferating cells,
we have assessed cell proliferation in the adult brain neurogenic
areas of mice with a KO of the CRMP5 gene (CRMP5
2/2 mice)
(Fig. 3 A, B). Following a short-pulsed BrdU incorporation assay
(2 hours), the number of proliferating BrdU-positive cells was
significantly increased in both neurogenic areas in CRMP5
2/2
mice when compared with wild type (WT) mice (Fig. 3 C–F) (SGZ:
Fig. 3D t-test p=0.045 / SVZ Fig. 3 F; t-test p=0.008). These
data show that CRMP5 takes part to the negative regulation of the
rate of cell proliferation in both adult brain neurogenic areas.
Suppression of CRMP 5 expression increases the number
of newly generated neurons in the adult olfactory bulb
and dentate gyrus
The CRMP5-positive neuroblasts generated in the adult
neurogenic areas give rise to newborn neurons which migrate,
survive and integrate the neuronal networks of the OB and DG.
So, we have investigated the rate of neurogenesis in WT and
CRMP5
2/2 mice by analyzing the number of newly generated
BrdU-labeled cells in the OB and the DG, 21 days after BrdU
administration. We found that the number of BrdU-labeled
newborn cells was higher in the CRMP5
2/2 mice compared to
WT in both the DG (+51%; t-test p=0.015; Fig. 4 A,C) and the
OB (+35%; t-test p=0.038; Fig. 4 B,D). In order to test the
contingent effect of the lack of CRMP5 on the fate of these
newborn cells, we assessed the number of BrdU-positive cells
co-localizing the neuronal marker NeuN in the DG (Fig. 4 E,F)
and the OB (Fig. 4 G,H). In both cases, the number of newborn
neurons increased significantly in CRMP5
2/2 mice (DG: +60%,
t-test p=0.027, Fig. 4 E,F; OB: +41%, t-test p=0.005, Fig. 4
G,H), indicating that neurogenesis was stimulated in both
neurogenic areas. However, the proportion of 21 days-old
BrdU-positive cells with a neuronal phenotype (co-expressing the
neuronal marker NeuN) was not significantly modified in
CRMP5
2/2 mice (OB: 90.863.6% in WT versus 94.762.8% in
KO mice, p=0.211; GD: 83.567.7% in WT versus 80.966.2%
in KO mice, p=0.40; data not shown). As a consequence, these
results show that the lack of CRMP5 stimulated neurogenesis
without affecting significantly the ratio of neuronal versus non-
neuronal newborn cells in the target areas.
Suppression of CRMP5 expression increases neuronal cell
death in the olfactory bulb and dentate gyrus
Following the observation of an increased rate of neurogenesis
in CRMP5
2/2 mice, and given the regulated balance between
neuronal proliferation and death in the OB [18] and the DG [19],
we later assessed the putative effects of the lack of CRMP5 on cell
apoptosis in both neurogenic areas of the adult brain. The rate of
cell death has been estimated using the cleaved form of caspase-3
as a reliable marker of apoptosis [20,21]. In addition, the volumes
of the OB and DG granule cell layers have been measured and
compared between WT and CRMP5
2/2 mice. In CRMP5
2/2
mice, we observed a significant volume decrease (about 30%) of
the OB granule cell layer (Fig. 5A; t-test p=0.00014), whereas the
DG granule cell layer remained unaffected (Fig. 5B; t-test p=
0.420). In accordance with this volume decrease, the number of
apoptotic (caspase-3 positive) cells in the OB granule cell layer was
significantly higher in CRMP5
2/2 mice compared to the WT
(Fig. 5C; t-test p=0.0018). In the DG granule cell layer of
CRMP5
2/2 mice, a less intense but significant increase of
apoptotic cell number was also observed (Fig. 5D; t-test p=
0.049), in spite of the unchanged global volume of the layer
(Fig. 5B).
In order to assess the rate of neuronal death, we estimated by
double immunolabeling the number of cells co-expressing caspase-
3 and the neuronal marker NeuN. In the OB of CRMP5
2/2 mice,
we found a strong increase of the absolute number of dying
neurons (caspase-3/NeuN-positive) (Fig. 5E, F; t-test p=0.007)
without modification of the ratio of neuronal vs non-neuronal
phenotypes in apoptotic cells (percentage of caspase-3/NeuN
positive cells in WT: 69.160.9% versus 67.464.8% in KO mice,
p=0.21). As a consequence of neuronal degeneration in the OB
granule cell layer of CRMP5
2/2 mice, we found a significant
decrease of the area of NeuN-immunoreactive profiles (relative to
the total area) in this layer (WT: 0.3260.007% versus KO:
0.3060.01%; t-test p=0.049; data not shown).
In the DG we could not observe any dying cells (caspase3-
positive) co-expressing NeuN, suggesting that neurons died before
becoming mature in this area.
Discussion
CRMP5 expression in neurogenic areas of the adult brain
In both neurogenic areas of the adult brain, the expression of
CRMP5 is restricted to a minor fraction of neuroblasts that
continue to divide (about 18% in the SVZ and 30% in the SGZ)
and to all the post-mitotic neuroblasts while they migrate and
reach their targets (OB and DG respectively). This observation is
reminiscent of our previous finding that CRMP5 was the most
abundant CRMP expressed by immature neurons in the adult
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e23721Figure 2. Immunofluorescence labeling of CRMP5 expression in neuroblasts of the mouse hippocampal neurogenic area. (A,B)
Confocal microscopy of immuno-labelled sections showing CRMP5-positive cells in the subgranular zone (SGZ) of the dentate gyrus (DG) in the
hippocampus. (C–N) Double immunolabeling in the DG of CRMP5 with the glial markers GFAP (C–E) and S100 (F–H) demonstrates that glial cells
never expressed CRMP5 (2E and 2F, arrows). In contrast, all CRMP5-positive cells co-expressed doublecortin (DCX) a selective marker of immature
neurons (or neuroblasts) (I–K, arrow). Finally, double immunolabeling of CRMP5 and KI67, a marker of cycling cells, shows that some CRMP5-positive
cells are still mitotic (L–N, arrow), whereas others are no longer proliferative. Granular cell layer (GCL); Hilus (Hi). Optical thickness of the confocal
planes=1 mm. Scale bars 50 mm (A,B); 20 mm (C–E); 15 mm (F–N).
doi:10.1371/journal.pone.0023721.g002
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CRMP2, CRMP5 expression is down-regulated when newly
generated neurons reach maturity [13,14]. Furthermore, CRMP5
is temporally and spatially co-expressed with DCX, PSA-NCAM
and TUC/CRMP4 which are considered as reliable markers of
neuroblasts and immature neurons in adult neurogenic areas
[15,17,22]. These statements lead us to the proposal that CRMP5
could be further used as a reliable marker of immature cells of the
neuronal lineages in the adult brain, at least in the olfactory and
hippocampal neurogenic areas.
The restriction of CRMP5 expression to immature newborn
neurons in the adult neurogenic areas supports the previous
assumptionthatthisproteinwasinvolved inneuronaldifferentiation,
at both developmental and adult stages [12,13]. However, about
18% of CRMP5-expressing cells in the SVZ and 30% in the SGZ
were still cycling and most likely belong to a transit amplifying
neuroblast population. This original finding is in favor of a role of
CRMP5 in the transition phase between proliferative and non-
proliferative stages, suggesting that CRMP5 might play an active
role in adult neurogenesis by taking part to the repression of
proliferation and/or to the induction of the first stages of neuronal
differentiation. The high expression level of CRMP5 in aggressive
neuroendocrine tumors [23] highlights the likely involvement of this
protein in the balance between proliferation and differentiation in
different cell types and in both physiological and pathological
conditions.
Figure 3. Suppression of CRMP5 expression in CRMP5
2/2 mice increases cell proliferation in the adult brain neurogenic areas. (A,B)
Immunofluorescence detection of CRMP5 in the dentate gyrus (3A) and SVZ (3B) confirms the lack of CRMP5 expression in CRMP5
2/2 mice in
comparison to wild type mice (WT). (C) Immunocytochemical labeling of BrdU-positive cells in the SGZ of the dentate gyrus (DG) of WT and CRMP5
2/2
mice, 2 hours after BrdU injections. Hilus (Hi); Granular cell layer (GCL). Scale bar 100 mm. (D) Increased total number of BrdU positive cells in the DG of
CRMP5
2/2 mice.Values areexpressedasmean + SEM. Student t-test. * p,0.05;**p,0.01.(E) ImmunocytochemicallabelingofBrdU-positive cellsin the
subventricular zone (SVZ) of WT and CRMP5
2/2 mice, 2 hours after BrdU injections. Lateral ventricles (LV). Scale bar 100 mm. (F) Increased total number
of BrdU positive cells in the SVZ of CRMP5
2/2 mice. Values are expressed as mean + SEM. Student t-test. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0023721.g003
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in proliferation, differentiation and survival of neurons
Adult neurogenesis is a dynamic process regulated by a finely
tuned balance between sequential events like stem cell and
progenitors proliferation, migration, differentiation, and cell
death or survival of neuroblasts and immature neurons (review
in [15]). In CRMP5
2/2 mice, the proliferation of progenitors
and the number of migrating neuroblasts increased significantly
(and in similar proportions) in both neurogenic areas. Comple-
mentary to the observation that CRMP5 expression starts at the
latest stages of proliferation in WT mice, this finding strongly
suggests that CRMP5 could participate to intracellular signaling
pathways that regulate negatively the proliferation of transient
amplifying cells and/or young neuroblasts. Since the increased
number of newborn neurons (NeuN-positive) in the OB of
CRMP5
2/2 mice was similar to the excess of neuroblasts in their
SVZ, the lack of CRMP5 has not interfered with the migration of
neuroblasts towards the olfactory bulb. Thus, we may assume
that CRMP5 is most likely not involved in the regulation of
migration of neuroblasts and immature neurons in the adult
brain. The fate of neural progenitors (neuronal versus non-
neuronal lineages) seems no more dependent of CRMP5 since the
ratio of these phenotypes was not altered in newly generated cells
of CRMP5
2/2 mice.
It is worth noting that the overflow of newborn neurons in
neurogenic areas of adult CRMP5
2/2 mice was followed by a
strong increase of apoptotic neuronal death in target areas, and
even a significant volume decrease of the granule cell layer in the
OB. In the DG, the increased rate of cell death did not result in a
decrease of the granule cell layer volume, probably due to the
lower rate of neurogenesis in this cortex and its reduced structural
impact [24].
Our observation of a strong increase of neuronal apoptosis in
CRMP5
2/2 mice argues for the involvement of CRMP5 in the
regulation of their survival. In the OB of WT mice, we have
previously shown that CRMP5 is mainly restricted to cell bodies of
neuroblasts lying in the subventricular zone and to the apical
dendrites of bulbar immature interneurons at the earliest stages of
their radial migration and differentiation [13]. Thus, we might
assume that CRMP5 could be essential for a differentiation
process determining the ability of immature interneurons to
integrate the local neuronal networks for becoming functional and
survive. This assumption is supported by the recent demonstration
of aberrant morphology and reduced diameter of Purkinje cell
dendrites from post-natal day 21 in CRMP5
2/2 mice [25]. Thus,
the post-natal maturation of Purkinje cells, as the maturation of
newly generated interneurons in the adult OB, seems most likely
submitted to CRMP5-dependent mechanisms occurring in their
dendrites.
The rise of neuronal apoptosis in CRMP5
2/2 mice must be
interpreted relative to the increase of proliferation and to the
resulting excess of incoming neuroblasts in the OB and DG. In the
cerebellum of juvenile CRMP1
2/2 mice, the lack of CRMP1
induced a decrease of granule cell proliferation and a strong
reduction of the apoptosis of newborn neurons [26]. Although
CRMP1 and CRMP5 deficiencies resulted in opposite effects on
neurogenesis (via proliferation and death) in the juvenile
cerebellum and adult neurogenic areas respectively, proliferation
and apoptosis of newborn neurons are similarly co-regulated in
both cases, in order to maintain a steady population of newly
generated neurons. The expression profiles of CRMP1 and
CRMP5 have been shown to overlap accurately during brain
development, although CRMP5 cannot interact directly with
CRMP1 [7]. In the adult OB, CRMP1 has been co-localized with
CRMP5 in the neuroblasts of the olfactory subependymal layer,
but CRMP5 concentrates in the apical dendrites of immature
newborn granule cells while CRMP1 remains mainly in their
pericarya [13]. Thus, CRMP5 and CRMP1 might contribute
synergistically to the regulation of the balance between functional
integration and death of newborn neurons in the adult neurogenic
areas, via pathways excluding direct molecular interaction
between these two proteins.
The contribution of CRMP5 to the maturation of newborn
neurons in neurogenic areas might be crucial for local information
processing in the DG and OB since CRMP5
2/2 mice display
impairments of long-term depression in Purkinje cells and
behavioral motor disorders [25]. Furthermore, CRMP1
2/2 mice
exhibit impaired long-term potentiation in the hippocampus and
spatial learning deficits [27]. These data argue for a major role of
CRMPs, including CRMP5, in dendritic plasticity, with important
implications for the maturation and functionality of networks
involving newborn neurons in neurogenic areas of the adult brain.
Mechanisms of CRMP5 involvement in adult
neurogenesis
The present study provides the first evidence that CRMP5 is a
likely key intracellular signal of neurogenesis regulation, not only
during brain development, but also in neurogenic areas of the
adult brain. CRMP5, the most recently identified member of the
CRMPs family [7–9], is strongly expressed in the developing
brain, but is restricted to neurogenic areas in the adult brain
[9,13]. The spatial and temporal patterns of CRMP5 expression
led authors to assume its functional involvement in neuronal
migration/differentiation [9], and more specifically in axonal
growth during development [11,12]. The present study empha-
sizes the role of CRMP5 in the balanced regulation of neuroblast
proliferation and survival of immature newly generated neurons,
in the DG and OB of the adult brain. Whether these functions
mimic those assumed by CRMP5 in the developing brain remains
to be elucidated, but we can assume that axonal growth is not a
major functional target of CRMP5 in the olfactory neurogenic
area since the main population of CRMP5-positive immature
newborn neurons differentiate into granule cell interneurons
which belong to the family of amacrine interneurons lacking a
typical axon. By contrast, CRMP5 concentrates in the apical
dendrite of immature granule cells and probably contributes to the
maturation and synaptic connectivity of these dendrites which play
a major role in the local processing of sensory information [18].
Figure 4. Suppression of CRMP5 expression increases the rate of newly generated neurons in the adult olfactory bulb and dentate
gyrus of CRMP5
2/2 mice. (A,B) Immunocytochemical labeling of BrdU-positive cells in the DG (A) and in the OB (B) of WT and CRMP5
2/2 mice, 21
days after BrdU injections. Hilus (Hi); Granular cell layer (GCL); Subependymal layer (SEL). Scale bar 100 mm. (C,D) Increased total number of BrdU
positive cells in the DG (C) and in the OB (D) of CRMP5
2/2 mice. Values are expressed as mean + SEM. Student t-test. * p,0.05; ** p,0.01. (E).
Immunocytochemical labeling of BrdU-NeuN double-labeled cell in the DG of WT mouse (arrow, step size of confocal Z planes=1 mm). Scale bar
15 mm. (F). Total number of BrdU-NeuN positive cells is increased in the DG of CRMP5
2/2 mice. Values are expressed as mean + SEM. Student t-test. *
p,0.05; ** p,0.01. (G). Immunocytochemical labeling of BrdU-NeuN double-labeled cell in the GCL of the OB of WT mouse (arrow, step size of
confocal Z planes=1 mm). Scale bar 15 mm. (H). Total number of BrdU-NeuN positive cells is increased in the OB of CRMP5
2/2 mice. Values are
expressed as mean + SEM. Student t-test. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0023721.g004
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survival of newly generated neurons in the DG and OB? First, we
should notice that CRMP5 is co-expressed with the other
members of the CRMP family, CRMP1, CRMP2 [13] and
CRMP4 [2], in neuroblasts and immature neurons of adult brain
neurogenic areas. As discussed above, CRMP1 and CRMP5 have
opposite effects on proliferation and survival of newborn neurons,
and they might contribute to the balance between neuronal
proliferation and death through different pathways, since they
cannot interfere with each other [6]. By contrast, interactions
between CRMP5 and CRMP2 are most likely to occur. CRMP2 is
the best known CRMP, and several studies demonstrated its
involvement in the promotion of axonal growth and neuronal
polarity through direct binding to tubulin and promoting
microtubule dynamics [28,29]. CRMP5 has been often found
associated with CRMP2 and it has recently been shown to display
opposite capacities, like inhibition of tubulin polymerization and
neurite outgrowth [6]. Moreover, CRMP5 is able to abrogate the
neurite outgrowth promotion induced by CRMP2, as a dominant
signal [6]. Thus, CRMP2 and CRMP5 have antagonistic effects
on crucial cellular events related to neuronal differentiation and
maturation, and probably take part synergistically to these
processes in both neurogenic areas of the adult brain. As a
dominant signal, CRMP5 likely plays a major role in the
regulation of adult neurogenesis by other CRMPs, particularly
CRMP2.
Indeed, many intrinsic and extrinsic factors have been identified
as potential regulators of neural proliferation and/or neuronal
differentiation in the adult OB or DG [15]. In addition to a
CRMP5 influence on proliferation or differentiation through a
direct impact on cytoskeletal proteins, or through a modulation of
other CRMPs, we cannot rule out the possibility that CRMP5
might interact with other signals like neurotrophins. The brain-
derived neurotrophic factor (BDNF) has long been identified as
playing several crucial functions in neuron survival, dendritic
development or neuronal plasticity, in both the adult neurogenic
areas, SGZ [30] and SVZ [31]. A study using CRMP5
2/2 mice
has recently brought support to a possible interaction between
CRMP5 and BDNF in the regulation of adult neurogenesis [25].
The stimulating effect of BDNF was impaired in cultured
hippocampal neurons from CRMP5
2/2 mice, and CRMP5 was
tyrosine phosphorylated by the high affinity BDNF receptor,
TrKB. However, further in vivo studies are now needed for the
elucidation of CRMP5 involvement in the regulation of BDNF
impact on neurogenesis and neuronal differentiation in the adult
brain neurogenic areas.
Finally, the present study provides the first evidence that
CRMP5 is a likely key intracellular signal of neurogenesis
regulation, not only during brain development, but also in
neurogenic areas of the adult brain. CRMP5 is a negative
regulator of the proliferation of neural progenitors and transit
amplifying neuroblasts, contrary to CRMP1 which stimulates
proliferation. However, CRMP5 likely takes part to neuronal
differentiation events which facilitate the integration of newborn
neurons in the local networks, and their survival, through a direct
action on cytoskeletal proteins. In addition, CRMP5 could also
interfere with CRMP2 effects on neurite outgrowth or other
aspects of neuronal differentiation. Further studies should
contribute to elucidate other signaling pathways in which CRMP5
could participate, and to assess the functional relevance of its
expression in activity-dependent plasticity that occurs in the
olfactory bulb and the hippocampus.
Materials and Methods
Generation of CRMP5
2/2 mice
Mice deficient in the CRMP5 gene were generated as described
previously [25]. Heterozygous animals were identified by geno-
typing, and bred together to produce homozygous mutant mice.
The CRMP5
2/2 mice appeared normal, without any obvious
gross abnormalities, and they reproduced normally. The absence
of expression of CRMP5 was confirmed in these animals by
immunohistochemistry, immunoblot analysis and RT-PCR anal-
yses [25]. All animals were housed under a 12-h light/dark cycle
with food and water available ad libitum. All efforts were made to
minimize the number of animals used and their suffering during
experimental procedure in accordance with NIH guidelines
concerning the Care and Use of Laboratory Animals and with
the approval of the Institutional Animal Care and Use Committee
of the University of Central Florida.
BrdU administration
10 adult 12-week-old male mice (5 WT and 5 CRMP5
2/2)
received two injections, 2 hours apart, of 5-bromo-29deoxyuridine
(BrdU Sigma Saint Louis MO; 50 mg/kg in physiological saline)
2 hours before killing, to assess cell proliferation. To assess
newborn cell survival, another series of 10 mice (5 WT and 5
CRMP5
2/2) received three BrdU injections every 2 hours before
being returned to their respective cages for the remaining 21 days
of the experiment.
Tissue processing and sectioning
Animals were deeply anesthetized with isoflurane gas and
perfused transcardially with a fixative solution of 4% paraformal-
dehyde in 0.1 M phosphate buffer, pH 7.4 (PB). Brains were
dissected out and fixed overnight at 4uC, washed 12 h in PB and
immersed 72 h at 4uC in PB containing 20% sucrose, then frozen
in chilled isopentane (255uC). Coronal sections (14 mm) were
made in a cryostat (Leica) and collected on Superfrost Plus slides.
Immunohistochemistry
CRMP5 double labeling. For double immunolabeling
associating KI67 or Doublecortin (DCX) with CRMP5, brain
sections were firstly heated for 20 min at 98uC in Target Retrieval
Figure 5. Suppression of CRMP5 expression increases neuronal cell death in the olfactory bulb and dentate gyrus of CRMP5
2/2
mice. (A,B) Stereological measurements of the volume of granular cell layers in the OB (A) and the DG (B) of wild type (WT) and CRMP5
2/2 mice. In
the OB (A), the lack of CRMP5 in CRMP5
2/2 mice induced a significant reduction of the granule cell layer thickness (*** p,0.005) when compared to
the wild type. DAPI-stained coronal sections of the OB failed to reveal other major morphological alterations in KO mice (Scale bar 400 mm). In the DG
(B), the thickness of the granule cell layer was similar in the CRMP5
2/2 and wild type mice. DAPI-stained coronal sections of the dorsal hippocampus
failed to reveal any major morphological alterations in CRMP5
2/2 mice (Scale bar 400 mm). All values are expressed as mean + SEM. Student t-test:
*** p,0.005. (C,D). Increased number of caspase-3 positive (apoptotic) cells in the OB (C) and in the DG (D) of CRMP5
2/2 mice when compared to
the wild type (WT). Values are expressed as mean + SEM. Student t-test. * p,0.05; *** p,0.005. (E). Confocal microscopy of a caspase-3/NeuN
immunolabeled cell (apoptotic neuron) in the DG of WT mouse (arrow, step size of confocal Z planes=1 mm). Scale bar 15 mm. (F). Increased total
number of caspase-3/NeuN immunoreactive cells in the OB of CRMP5
2/2 mice when compared to wild type (WT) mice. Values are expressed as mean
+ SEM. Student t-test. ** p,0.01.
doi:10.1371/journal.pone.0023721.g005
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90 min with blocking solution (2% BSA, 0.3% Triton, 5%
serum) and incubated overnight at 4uC with primary antibodies.
The primary antibodies used in this study were the rabbit anti-
CRMP5 antibody (2 mg/ml) previously manufactured in our
laboratory [4,9,13], rabbit anti- CRMP4 (1/500; Chemicon,
Millipore, Billerica, MA, USA), guinea pig anti-DCX (1/1000;
Chemicon, Millipore, Billerica, MA, USA), mouse anti-PSA-
NCAM (1/100; AbCys, Paris, France), mouse anti-KI67 (1/100,
Novacastra, Newcastle,UK), mouse anti-GFAP (1/200, DAKO),
mouse anti-S100b (1/400, Sigma) and mouse anti-Nestin (1/200,
Pharmingen, San Lose, CA). Finally, the sections were incubated
for 2 hours in species-specific secondary antibodies conjugated to
Alexa 488, 546 or 633 (Molecular Probes, Invitrogen, Eugene,
OR, USA), for immunofluorescence labeling.
BrdU and Caspase 3 labeling. For BrdU immunocyto-
chemistry, brain sections were pre-incubated in Target Retrieval
Solution for 20 min at 98uC. Aftercoolingfor20 min, sections were
treated with Triton 0.5% in phosphate-buffered saline (PBS) for
30 min, then for 3 min with pepsin (0.43 U/ml in 0.1 N HCl;
Sigma). Further, endogenous peroxidases were blocked with a
solution of 3% H2O2 in 0.1 M PBS and the sections were then
incubated for 90 min in 5% normal serum (Vector Laboratories),
5% bovine serum albumin (Sigma) and 0.125% Triton X-100 to
blocknonspecificbinding.BrdUorCaspase3immunolabelingwere
obtained by incubating the sections overnight at 4uC in a mouse
anti-BrdU primary antibody (1/100; Chemicon) or 48 h at 4uCi na
Rabbit Anti-Caspase 3 (Casp3) (1/500; Cell Signaling Technology).
For BrdU detection, the sections were then incubated for 2 h at
room temperature in a horse biotinylated anti-mouse (1/200;
Vector Laboratories) whereas for caspase 3 detection they were
incubated in a goat anti-rabbit (1/200; Vector Laboratories)
secondary antibody. The sections were then processed with
avidin-biotin-peroxidase complex (ABC Elite Kit; Vector
Laboratories) for 30 min, followed by three rinses of 5 min in
PBS. Finally, they were reacted in 0.05% 3,30-diaminobenzidine-
tetrahydrochloride (Sigma), 0.03% NiCl2, and 0.03% H2O2 in
Tris-HCl buffer (0.05 M, pH 7.6), dehydrated in graded ethanols,
and coverslipped in DPX.
For BrdU and Casp3 double-labeling experiments, the sections
were treated as described before except that they were incubated
simultaneously with mouse anti-NeuN antibodies (1/500; Chemi-
con), guinea pig anti-DCX (1/1000), mouse anti-GFAP (1/200) or
rat anti-BrdU (1/100; Oxford Biotechnology, Abcys) at 4uC
overnight. Immunoreactivities were revealed for 2 hours using
species-specific secondary antibodies conjugated to Alexa 488, 546
or 633 or biotinylated secondary antibodies followed by strepta-
vidin Alexa 488 (Molecular probe).
Quantification and image analysis
Number and density of BrdU- and Casp3-labelled
cells. Immunolabeled profiles were counted in 14 mm-thick
coronal sections under a Zeiss microscope coupled with a specific
mapping software (Mercator Pro; Explora Nova, La Rochelle,
France). The brain areas of interest were the granular, and
subependymal layers of the OB (five sections per animal, inter-
section intervals of 336 mm), the granular layer of the DG (five to
seven sections per animal, inter-section intervals of 336 mm) and
the forebrain SVZ (four sections per animal; inter-section intervals
of 336 mm). The volume of each brain area was calculated
according to a conventional stereological equation [32] as
described previously [20]. The density (number of cells/mm
2)
and the total number of labeled cells were inferred from these data
as described previously. All the data were averaged across animals
within each experimental group and statistical differences were
assessed using a Student t-test.
NeuN labeling analysis. Images of NeuN immuno-
fluorescence were digitized with a 640 objective within the
granular cell layer of the OB (4 images per section and 5 sections
per mouse spaced by 336 mm). Within a randomly selected
squared zone (constant area) inside the granular cell layer, the total
area of immunoreactive profiles was calculated after an image
segmentation procedure (binarization) using a constant threshold
value of fluorescence signal. The values of immunoreactive areas
obtained were expressed as a percentage of the total sampled area
and averaged within each experimental group, as performed
before [33].
Double labeling analysis and quantification. Double-
labeled sections were analyzed using a TCS SP2 confocal laser
microscope (Leica) at the Centre Commun de Quantime ´trie
(Universite ´ Claude Bernard-Lyon1). The co-localization of
markers in individual cells was assessed in 15–30 cells from each
animal by performing z-stack acquisitions and three-dimensional
reconstructions using the softwares QWin (Leica) and Adobe
Photoshop, version CS (Adobe system, San Jose, CA).
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